FY2025 · ended Dec 31, 2025 · Revenue $1.29B, +10.4% YoY · Filed Feb 27, 2026
Progyny, Inc. (PGNY) files with the SEC under industry code 8090, Services-Misc Health & Allied Services, NEC. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.3 billion and net income of $58.5 million. Free cash flow was $191.8 million. As of Sep 30, 2026 it held $195.6 million in cash and investments and $25.9 million in total debt.
Revenue (TTM)
$1.34B
+5.5% vs year-ago TTM
Net income (TTM)
$91.02M
+60.9% vs year-ago TTM
Operating cash flow (TTM)
$207.18M
-0.5% vs year-ago TTM
Free cash flow (TTM)
$179.64M
-7.1% vs year-ago TTM
EPS (TTM)
$1.08
+73.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
81.90M
-4.1% vs prior year
Net cash
$169.73M
as of Sep 30, 2026
Operating margin
9.4%
FY 2026
Company profile
- Industry
- Services-Misc Health & Allied Services, NEC (SIC 8090)
- Listed as
- PGNY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1551306
- Former names
- Auxogyn, Inc. (until Mar 19, 2015); Auxogyn Inc (until Sep 16, 2013)
Other Services-Misc Health & Allied Services, NEC companies
- Fresenius Medical Care AG FMS
- Davita Inc. DVA
- Sotera Health Co SHC
- agilon health, inc. AGL
- Charming Medical Ltd MCTA
- Viemed Healthcare, Inc. VMD
- Park Dental Partners, Inc. PARK
- Marpai, Inc. MRAI
All 15 Services-Misc Health & Allied Services, NEC companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.3B | $1.2B | $1.1B | $786.9M | $500.6M |
| Operating income | $85.3M | $67.5M | $62.2M | $23.3M | $32.3M |
| Net income | $58.5M | $54.3M | $62.0M | $30.4M | $65.8M |
| Diluted EPS | $0.65 | $0.57 | $0.62 | $0.30 | $0.66 |
| Operating cash flow | $210.2M | $179.1M | $188.8M | $80.4M | $26.0M |
| Free cash flow | $191.8M | $173.7M | $185.2M | $77.2M | $23.9M |
| Total assets | $742.4M | $607.1M | $756.6M | $543.0M | $358.1M |
| Total liabilities | $226.4M | $185.0M | $203.2M | $166.0M | $106.2M |
| Stockholders' equity | $516.0M | $422.1M | $553.4M | $377.0M | $251.8M |
| Cash and investments | $310.1M | $228.0M | $371.1M | $189.3M | $119.4M |
| Total debt | $27.7M | $19.3M | $19.4M | $7.7M | $8.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 27, 2026 | May 21, 2026 |
| 8-K |
Current report
Other events
|
May 26, 2026 | May 26, 2026 |
All 937 Progyny, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.